HUTCHMED (China) Limited
HealthcareNASDAQ:HCM · NASDAQ Global Select
+$0.28 today
Vol 0.03M · Avg 0.04M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$602.2M of revenue converted into $466.9M of net income for the selected period. Gross margin is 15.5% and net margin is 82.8%, showing how much revenue survives after costs and taxes. EPS is $2.69, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $550.0M -12.7% | $630.2M -24.8% | $838.0M +96.5% | $426.4M +19.7% | $356.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $337.2M -3.3% | $348.9M -9.3% | $384.4M +23.6% | $311.1M +20.5% | $258.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $212.7M -24.4% | $281.3M -38.0% | $453.6M +293.3% | $115.3M +17.8% | $97.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 38.7% -6.0pp | 44.6% -9.5pp | 54.1% +27.1pp | 27.0% -0.4pp | 27.5% | 9.8% | 28.9% | 38.3% |
| Research & Development | $164.1M -23.1% | $213.4M -29.6% | $303.1M +13.3% | $267.6M +29.0% | $207.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $103.3M -8.5% | $112.9M -15.2% | $133.2M -2.2% | $136.1M +7.1% | $127.1M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $267.4M -16.9% | $321.9M -26.2% | $436.2M -16.6% | $523.0M +22.7% | $426.2M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $13.3M +8.1% | $12.3M +50.4% | $8.2M -5.3% | $8.7M +20.5% | $7.2M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$41.4M -31.9% | -$31.4M -218.0% | $26.6M +106.6% | -$401.1M -92.9% | -$208.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -7.5% -2.5pp | -5.0% -8.1pp | 3.2% +97.2pp | -94.1% -35.7pp | -58.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$54.7M -25.2% | -$43.7M -337.9% | $18.4M +104.5% | -$409.8M -24.8% | -$328.3M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -10.0% -3.0pp | -6.9% -9.1pp | 2.2% +98.3pp | -96.1% -3.9pp | -92.2% | 16.6% | 24.1% | 22.0% |
| Interest Income | $50.0M +24.8% | $40.1M +10.9% | $36.1M +276.5% | $9.6M +362.4% | $2.1M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.9M +0.0% | $2.9M +278.4% | $759.0K +16.4% | $652.0K +10.1% | $592.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $577.4M +548.3% | $89.1M +2.1% | $87.2M +69.3% | $51.5M -70.3% | $173.2M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $522.7M +1052.3% | $45.4M -57.0% | $105.6M +129.3% | -$360.2M -131.9% | -$155.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 95.0% +87.8pp | 7.2% -5.4pp | 12.6% +97.1pp | -84.5% -40.9pp | -43.6% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $63.8M +786.8% | $7.2M +59.5% | $4.5M +1693.3% | -$283.0K -102.4% | $11.9M | $1.3B | -$1.6B | $745.2M |
| Net Income | $458.1M +1114.2% | $37.7M -62.6% | $100.8M +127.9% | -$360.8M -85.4% | -$194.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | 83.3% +77.3pp | 6.0% -6.0pp | 12.0% +96.6pp | -84.6% -30.0pp | -54.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $3 +1104.5% | $0 -63.3% | $1 +127.9% | -$2 -72.0% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $3 +1081.8% | $0 -63.3% | $1 +127.9% | -$2 -72.0% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $171.7M +0.3% | $171.1M +0.7% | $169.9M +0.3% | $169.4M +6.9% | $158.5M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $174.6M +0.0% | $174.6M +0.4% | $173.8M +2.6% | $169.4M +6.9% | $158.5M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cidara Therapeutics, Inc.
CDTX
$5.61B
Scholar Rock Holding Corporation
NASDAQ:SRRK
$5.29B
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
$3.90B
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
$2.82B
Supernus Pharmaceuticals, Inc.
NASDAQ:SUPN
$2.58B
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
$2.55B
Bausch Health Companies Inc.
NYSE:BHC
$1.89B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.57B
Perrigo Company plc
NYSE:PRGO
$1.52B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does HCM generate?
HUTCHMED (China) Limited (HCM) reported $549.96M of revenue in fiscal 2025.
Is HCM profitable?
HUTCHMED (China) Limited (HCM) reported $458.12M of net income, with a net margin of 83.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.